5-Bromo-3-hydroxy-1-isopropylpyrazole-4-carboxylic acid ethyl ester | 678995-01-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Bromo-3-hydroxy-1-isopropylpyrazole-4-carboxylic acid ethyl ester
• 英文别名: Ethyl 5-bromo-3-hydroxy-1-isopropylpyrazole-4-carboxylate；ethyl 3-bromo-5-oxo-2-propan-2-yl-1H-pyrazole-4-carboxylate
• CAS: 678995-01-2
• 化学式: C₉H₁₃BrN₂O₃
• 分子量: 277.118
• InChiKey: VBMWIKKPOUWEGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-Bromo-3-hydroxy-1-isopropylpyrazole-4-carboxylic acid ethyl ester 、 溴甲苯 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 6.0h， 生成 3-Benzyloxy-5-bromo-1-isopropylpyrazole-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  EP1550668

  摘要：

  公开号：
• 作为产物：
  描述：

  3-Hydroxy-1-isopropylpyrazole-4-carboxylic acid ethyl ester 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 5-Bromo-3-hydroxy-1-isopropylpyrazole-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  EP1550668

  摘要：

  公开号：

文献信息

• Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
  申请人：Fujikura Hideki

  公开号：US20060128635A1

  公开（公告）日：2006-06-15

  The present invention provides pyrazole derivatives represented by the general formula: wherein R 1 represents H, an optionally substituted C 1-6 alkyl group etc.; one of Q and T represents a group selected from the following groups: and the other represents —(CH 2 ) n —Ar wherein Ar represents an optionally substituted C 6-10 aryl group or an optionally substituted C 1-9 heteroaryl group; and n represents an integral number from 0 to 2, an optionally substituted C 1-6 alkoxyl group, an optionally substituted amino group, an optionally substituted C 2-9 heterocycloalkyl group or an optionally substituted heterocycle-fused phenyl group; R represents an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 6-10 aryl group etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human 1,5-anhydroglucitol/fructose/mannose transporter and are useful as agents for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose or a disease associated with hyperglycemia (e.g., diabetic complications, diabetes, etc.), and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

  本发明提供了由下式表示的吡唑衍生物：其中，R1代表H、可选取代的C1-6烷基等；Q和T中的一个代表以下基团之一：另一个代表—(CH2)n—Ar，其中Ar代表可选取代的C6-10芳基基团或可选取代的C1-9杂环芳基基团；n表示0至2的整数、可选取代的C1-6烷氧基基团、可选取代的氨基基团、可选取代的C2-9杂环烷基基团或可选取代的杂环融合苯基团；R代表可选取代的C3-8环烷基基团、可选取代的C6-10芳基基团等，以及其药学上可接受的盐或前药，其在人类1,5-脱水葡萄糖/果糖/甘露糖转运体中表现出优异的抑制活性，并且可用作预防、抑制进展或治疗与葡萄糖、果糖和甘露糖中至少一种的过度摄取或高血糖相关的疾病的药物（例如糖尿病并发症、糖尿病等），以及包含它们的制药组合物、制药用途和其制备的中间体。
• PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE IN PRODUCING THE SAME
  申请人：Fujikura Hideki

  公开号：US20100029919A1

  公开（公告）日：2010-02-04

  The present invention provides pyrazole derivatives represented by the general formula: wherein R 1 represents H, an optionally substituted C 1-6 alkyl group etc.; one of Q and T represents a group selected from the following groups: , and the other represents —(CH 2 ) n —Ar wherein Ar represents an optionally substituted C 6-10 aryl group or an optionally substituted C 1-9 heteroaryl group; and n represents an integral number from 0 to 2 , an optionally substituted C 1-6 alkoxyl group, an optionally substituted amino group, an optionally substituted C 2-9 heterocycloalkyl group or an optionally substituted heterocycle-fused phenyl group; R represents an optionally substituted C 3-8 cycloalkyl group, an optionally substituted C 6-10 aryl group etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human 1,5 -anhydroglucitol/fructose/mannose transporter and are useful as agents for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose or a disease associated with hyperglycemia (e.g., diabetic complications, diabetes, etc.), and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

  本发明提供了由下式表示的吡唑衍生物： 其中R1表示氢、可选取代的C1-6烷基等；Q和T中的一个表示以下组之一：， 另一个表示—(CH2)n—Ar，其中Ar表示可选取代的C6-10芳基或可选取代的C1-9杂环芳基；n表示0到2的整数，可选取代的C1-6烷氧基、可选取代的氨基、可选取代的C2-9杂环烷基或可选取代的杂环融合苯基；R表示可选取代的C3-8环烷基、可选取代的C6-10芳基等，其药物可接受的盐或前药，其在人类1,5-脱水葡萄糖/果糖/甘露糖转运体中具有出色的抑制活性，并且可用作预防、阻止进展或治疗与葡萄糖、果糖和甘露糖中至少一种过量摄入或与高血糖症（例如糖尿病并发症、糖尿病等）相关的疾病的药物，以及包含它们的制药组合物、制药用途和其制备的中间体。
• Pyrazole derivative, drug composition containing the same and production intermediate therefor
  申请人：Kikuchi Norihiko

  公开号：US20070060531A1

  公开（公告）日：2007-03-15

  The present invention provides pyrazole derivatives represented by the general formula: wherein R 1 represents H, an optionally substituted C 1-6 alkyl, etc.; one of Q and T represents a group selected from the following: , and the other represents -Z-Ar wherein Z represents —O—, —S—, etc.; Ar represents an optionally substituted C 6-10 aryl, etc.; R represents an optionally substituted C 3-8 cycloalkyl, an optionally substituted C 6-10 aryl, etc., pharmaceutically acceptable salts thereof, and prodrugs thereof, which exhibit an excellent inhibitory activity in human sodium/glucose cotransporter (SGLT) and are useful as agents for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose (diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, etc.), and pharmaceutical compositions containing the same, medicinal uses thereof and intermediates for production therefor.

  本发明提供了由下式表示的吡唑衍生物： 其中R1代表H、可选地取代的C1-6烷基等；Q和T中的一个代表以下选组之一：，而另一个代表-Z-Ar，其中Z代表—O—、—S—等；Ar代表可选地取代的C6-10芳基等；R代表可选地取代的C3-8环烷基、可选地取代的C6-10芳基等，以及其药学上可接受的盐和前药。该衍生物在人类钠/葡萄糖共转运体（SGLT）中表现出出色的抑制活性，并且可用作预防、抑制进展或治疗与葡萄糖、果糖和甘露糖中至少一种碳水化合物过度摄入相关的疾病（糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症等）的药剂。还提供了包含该衍生物的药物组合物、其药用途途及其制备的中间体。
• EP1550668
  申请人：——

  公开号：——

  公开（公告）日：——
• US7576064B2
  申请人：——

  公开号：US7576064B2

  公开（公告）日：2009-08-18